Institutional Decay

RFK Jr urges Alzheimer’s screening but blunts key panel that could drive research

The health secretary called for better Alzheimer’s screening. But the expert panel that sets screening guidance has been blocked from meeting for more than a year.

Why this matters: The US health secretary, Robert F Kennedy Jr, has called for better Alzheimer’s screening – but a critical federal panel that might have helped researchers find practical ways to do that has been prevented from meeting for more than a year.

What happened

The health secretary, Robert F. Kennedy Jr., pushed for better Alzheimer’s screening in public remarks. At the same time, the US Preventive Services Task Force (USPSTF) has not met for over a year. The panel usually reviews screening rules that influence research, clinical practice, and insurance coverage.

A political appointee fired two taskforce chairs and vacancies went unfilled. That left the panel short of members and idle just as it planned a review on cognitive screening.

Who wins here

Political appointees and the department leadership gained control over the agency’s calendar and staffing. They can slow or speed work by choosing who sits on expert panels. The people who lose are researchers, clinicians, and older adults waiting for clear screening guidance.

Researchers also lose leverage. USPSTF draft recommendations shape studies and funding priorities. When the panel sits idle, research planning and debate slow.

How the play works

This is a power move using staff and appointments. The administration kept slots empty and removed leaders. That blocks the panel from meeting and blocks its recommendations from appearing.

USPSTF advice matters because insurers and Medicare often follow it. A stalled panel means fewer signals for researchers and less clarity on what tests doctors should offer.

Why it matters

Screening could detect cognitive decline earlier. But the evidence on routine screening is mixed. Expert review would sort the evidence, point out gaps, and steer real studies.

When a review is blocked, doctors and insurers face more uncertainty. Patients may miss earlier care, and scientists may delay studies that could find better tests or treatments.

What to watch next

Watch for new appointments to the USPSTF and any public meeting dates. Check whether draft screening guidance appears for public comment. Also watch NIH and CMS moves that could fund or pilot screening studies instead.

If the department names new members, note their backgrounds. That will show whether the panel is being rebuilt to work or to stay stalled.

LensInstitutional Decay
TypeReporting
PublishedJuly 26, 2026
Read time3 min read
SourceThe Guardian
Where the facts come from

The facts in this story were first reported by The Guardian. What you're reading here is our take on what it means for power and for you.

Read the original at The Guardian
Related topics

More stories on these topics

news analysisaccountability gapmediacongressnational
Subscribe for moreExplore this lensBrowse all issues